XTL Biopharmaceuticals Ltd.

Tel Aviv Stock Exchange XTLB.TA

XTL Biopharmaceuticals Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -8,713.58

XTL Biopharmaceuticals Ltd. Price to Earnings Ratio (P/E) is -8,713.58 on January 14, 2025, a -37,373.61% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

XTL Biopharmaceuticals Ltd. 52-week high Price to Earnings Ratio (P/E) is -22.23 on January 25, 2024, which is 99.74% above the current Price to Earnings Ratio (P/E).
XTL Biopharmaceuticals Ltd. 52-week low Price to Earnings Ratio (P/E) is -15,594.96 on December 20, 2024, which is -78.97% below the current Price to Earnings Ratio (P/E).
XTL Biopharmaceuticals Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -1,631.37.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Tel Aviv Stock Exchange: XTLB.TA

XTL Biopharmaceuticals Ltd.

CEO	Mr. Shlomo Spokone Shalev
IPO Date	Aug. 30, 2005
Location	Israel
Headquarters	5 Badner Street
Employees	8
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Key trends

Past 5 years